Archives
-
Synthetic DEFB1 mRNA Limits Cryptosporidium Infection
2026-09-01
The reference study uses synthetic, co-transcriptionally capped DEFB1 mRNA to increase β-defensin 1 production in human intestinal cells and reduce Cryptosporidium parvum infection in vitro. Its design links delivery verification, host-protein induction, parasite quantification, and viability testing, providing a useful framework for host-directed therapy research.
-
Açaí Extracts: Hepatocyte Cytotoxicity and Induction
2026-09-01
Raichura and colleagues evaluated consumer-relevant açaí extracts in human hepatocytes and complementary transporter cells, distinguishing extract-dependent cytotoxicity from drug-metabolizing enzyme or transporter induction. The findings suggest that selected preparations can compromise hepatocyte viability without significantly increasing CYP or transporter expression, providing a useful framework for botanical-drug interaction assessment.
-
SGC-CBP30 and the Epigenetic Logic of LUAD
2026-08-31
Super-enhancer hijacking can create transcriptional dependencies that are difficult to resolve with genomic profiling alone. This thought-leadership guide connects the LINC01977–TGF-β/SMAD3 axis in early-stage lung adenocarcinoma with SGC-CBP30, a selective CREBBP/EP300 bromodomain inhibitor, and outlines a disciplined path from mechanistic hypothesis to translational validation.
-
Ac-YVAD-CMK: Mapping Pyroptosis in Liver
2026-08-31
Ac-YVAD-CMK is a selective, irreversible caspase-1 inhibitor for dissecting pyroptosis, cytokine maturation, and liver inflammation. This article presents a causal assay framework that separates Kupffer-cell membrane repair from downstream inflammasome activity.
-
Vorinostat for HDAC Inhibition Workflows
2026-08-30
Build reproducible HDAC-inhibition experiments with Vorinostat, from DMSO stock preparation through chromatin, viability, and apoptosis readouts. The workflow also positions this benchmark compound against M344 for cancer biology research and helps distinguish cytostatic effects from mitochondrial cell death.
-
TBST for Antibody Assays: Workflow and Troubleshooting
2026-08-29
TBST combines Tris-buffered saline with Tween 20 to support lower-background Western blot, immunofluorescence, immunohistochemistry, and immunocytochemistry workflows. This practical guide connects buffer selection with a published uPAR·uPA inhibitor study, showing how disciplined washing and orthogonal readouts can strengthen conclusions about antibody-based assays.
-
Full-Length αvβ3 Integrin Conformations by Cryo-EM
2026-08-28
This cryo-EM study resolves an unusually broad set of full-length human αvβ3 integrin conformations in apo and ligand-bound states. Its dynamic structural model clarifies how intermediate states and inhibitor-specific recognition may influence integrin drug design, while also defining important limits for translating purified-protein structures into cellular mechanisms.
-
Baicalein: Mechanism, Evidence, and Research Use
2026-08-28
Baicalein, also called 5,6,7-trihydroxy-2-phenylchromen-4-one, is a flavonoid research compound associated with 12-lipoxygenase inhibition, apoptosis studies, and inflammation pathway modulation. Its product specifications support controlled biochemical and cell-based workflows, but they do not establish clinical efficacy or direct neuroprotective activity.
-
EGTA for Calcium Signaling Workflows
2026-08-27
EGTA, or egtazic acid, provides a practical way to test whether calcium availability drives neuronal, endothelial, or cell-death phenotypes. This guide connects selective calcium chelation with patch-clamp pharmacology, neuroprotection experiments, apoptosis assays, and troubleshooting for reproducible workflows.
-
AEBSF.HCl Workflows for Protease Research
2026-08-27
AEBSF.HCl enables controlled interrogation of serine-protease activity in cell lysis, APP processing, and regulated cell death assays. Its greatest value is as a broad, irreversible perturbation control—especially when paired with compartment-specific imaging and cathepsin-focused validation.
-
Ultrafiltration for Circular RNA Purification
2026-08-26
Guillen-Cuevas et al. evaluated ultrafiltration as a separation method for protein-encoding circular RNA produced by in vitro transcription and self-splicing. By measuring conformer-specific membrane transport and critical flux, the study achieved 86% purity with more than 50% yield, outperforming size-exclusion HPLC in the reported comparison.
-
ASB3 E3 Ligase Targets MAVS in Antiviral Immunity
2026-08-26
The 2024 Cell Death & Differentiation study identifies ASB3 as an inducible negative regulator of antiviral innate immunity that targets MAVS for K48-linked ubiquitination and proteasomal degradation. By integrating viral infection models, ASB3 perturbation, and molecular ubiquitination analysis, the work connects ASB3 activity to reduced TBK1–IRF3 signaling, interferon production, and host resistance to influenza infection.
-
Fluoxetine HCl: Bench Workflows for Serotonin Research
2026-08-25
This bench-focused guide shows how Fluoxetine HCl can connect serotonin transporter manipulation with 5-HT2C assays, reward behavior, neurogenesis and synaptic plasticity studies. It also explains why receptor potency, vehicle control and behavioral endpoint selection matter when translating cellular findings into depression research and stress resilience mechanisms.
-
SIRT1/2 Inhibitor IV: Research Workflows
2026-08-25
SIRT1/2 Inhibitor IV (cambinol) enables mechanism-driven studies of dual SIRT1/SIRT2 inhibition across protein acetylation, lactate-linked signaling, cancer-cell apoptosis, and tumor growth. This guide translates the Ran lactylation findings into practical assay designs while emphasizing target-engagement controls, dosing optimization, and the limits of cross-model interpretation.
-
PTPN2, STING–STAT3, and Autophagy in Psoriasis
2026-08-24
The reference study identifies PTPN2 as a psoriasis-relevant phosphatase that restrains a STING–STAT3 signaling axis and restores autophagy and apoptosis in keratinocytes. Using cellular experiments and an imiquimod-induced mouse model, the authors connect PTPN2 activity with reduced inflammatory cytokine production and attenuated psoriatic pathology, while highlighting rapamycin as a strategy that can enhance this response.